FDA, Indivior Say Braeburn Fibbing In Opioid Exclusivity Suit
By Jeff Overley ( June 5, 2019, 8:36 PM EDT) -- The U.S. Food and Drug Administration and Indivior Inc. are accusing Braeburn Inc. of exaggerating the science behind its opioid-addiction drug Brixadi in hopes of starting sales that are blocked by exclusivity for a rival drug marketed by Indivior....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.